Association between a TGFβ1 promoter polymorphism and the phenotype of aspirin-intolerant chronic urticaria in a Korean population

H. J. Park, Y. M. Ye, Gyu Young Hur, S. H. Kim, H. S. Park

Research output: Contribution to journalArticle

15 Citations (Scopus)


Background: Chronic urticaria/angioedema is a common phenotype in patients with aspirin sensitivity; however, its genetic mechanism is not understood. Transforming growth factor (TGF)β1 is a key regulatory cytokine involved in allergic inflammation. Objective: We examined the association of a TGFβ1 genetic polymorphism with aspirin-intolerant chronic urticaria (AICU) and aspirin-tolerant chronic urticaria (ATCU) in a Korean population. Methods: A promoter polymorphism in the TGFβ1 gene, TGFβ1 -509C>T, was analysed in 112 AICU patients, 153 ATCU patients and 457 normal controls (NC), and the frequency was compared among the groups. Serum TGFβ1 levels were measured by ELISA. Results: The minor allele frequency of the -509C>T polymorphism was significantly higher in patients with AICU compared with the other two groups (P < 0.02 for AICU vs. NC; P < 0.05 for AICU vs. ATCU). Among the AICU patients, those with the T allele tended to have lower serum TGFβ1 levels. Conclusion: These findings suggest that the -509C>T polymorphism in the TGFβ1 promoter may contribute to the development of the AICU phenotype.

Original languageEnglish
Pages (from-to)691-697
Number of pages7
JournalJournal of Clinical Pharmacy and Therapeutics
Issue number6
Publication statusPublished - 2008 Dec 1



  • Aspirin hypersensitivity
  • Chronic urticaria
  • Genetic polymorphism
  • Transforming growth factor β1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this